HDAC6 is a histone deacetylase that represses transcription and is involved in cell cycle progression, development, and regulation of gene expression. HDAC6 also plays an important role in cell migration in normal tissue and in cancer via its regulation of tubulin acetylation and depolymerization. Variable levels of HDAC6 dysregulation are associated with survival in different cancer types. For example, HDAC6 overexpression is associated positively with survival in ER-positive breast cancer, cutaneous T-Cell lymphoma and diffuse large B-Cell lymphoma, and with poor prognosis in peripheral T-Cell lymphoma and ER-negative breast cancer. Downregulation of HDAC6 is associated with poor survival in chronic lymphocytic leukemia. In immunohistochemistry of normal tissue, HDAC6 has broad cytoplasmic expression throughout the body, with strongest positivity in seminiferous duct cells and renal tubules. References: J Cancer Res Ther. 2014 Jul-Sep;10(3):469-78, PMID: 25313724; Cold Spring Harb Perspect Med. 2016 Oct; 6(10): a026831, PMID: 27599530; Oncogene. 2007 Aug. 26: 5420–5432, PMID: 17694083; J Cell Sci. 2007 Apr 15;120(Pt 8):1469-79, PMID: 17389687; J Breast Cancer. 2014 Dec; 17(4): 323–331, PMID: 25548579, PMID: 29180246